The Brazilian propolis produced by Apis mellifera called green, brown and red have great economic importance, due to their biological activities and export to several countries, such as Japan and China,and productionof approximately 200 tons per year. The main botanical origins of Brazilian propolis are: Baccharis dracunculifolia for green propolis; Araucaria sp, Eucalyptus sp and others for brown propolis; and Dalbergia ecastophyllum for the red propolis. In 2005, ANVISA published a technical note on the registration of products containing propolis, as well as the RDC no. 24/2011 authorizing the registration of propolis-based medicines. However, to date nonemedicine has been registered with ANVISA. There are many gaps to be filled, since ANVISA demands the execution of chemical, analytical, pharmacological and technological studies to guarantee safety, efficacy and quality in the development of new medicines. Thus, it is proposed to carry out complementary steps in phytochemical studies to obtain standardized extracts and compounds to be used in the development of analytical methods; in obtaining semi-synthetic derivatives; in stability and degradation studies; in bioaccessibility, biotransformation, pharmacokinetic and pharmacodynamic studies; in in silico studies to determine chemical structure-activity relationship and docking analyses; in the development of pharmaceutical formulations; in both in vitro and invivo toxicological studies; in studies of genotoxicity and mutagenicity; in anti-inflammatory, immunomodulatory, antimicrobial, antiparasitic, antiproliferative, healing and gastroprotective assays, among others. The ultimate goal of this proposal is to add value to the Brazilian beekeeping sector.
News published in Agência FAPESP Newsletter about the scholarship: